Short Bowel Syndrome Market size was valued at USD 1.61 billion in 2024 and is expected to reach USD 3.74 billion by 2032, growing at a CAGR of 11.16% over the forecast period of 2025-2032.
Rising incidence of gastrointestinal diseases, more incidences of bowel resections, and the growing SBS patient population dependent on parenteral nutrition owing to intestinal failure are driving strong worldwide short bowel syndrome market expansion.
The Crohn's & Colitis Foundation estimates that 10,000 to 20,000 Americans have short bowel syndrome; many of them depend on long-term parenteral support, which causes a major healthcare load. Reflecting high diagnosis rates and adoption of sophisticated short bowel syndrome therapeutics, the U.S. Short Bowel Syndrome market accounted for roughly 79% of the North American market in 2024. Rare illness therapies, including FDA-approved SBS drugs like teduglutide, which have changed the short bowel syndrome therapy market by lowering reliance on parenteral nutrition, have drawn more attention from government health agencies and regulatory authorities. Furthermore, impacting the favourable Short Bowel Syndrome market global development are campaigns raising awareness and better diagnosis.
Usually resulting from bowel resections or congenital abnormalities, Short Bowel Syndrome (SBS) is an uncommon, complicated gastrointestinal disease marked by malabsorption resulting from insufficient functional length of the small intestine. The condition causes major nutritional deficits and dependency on parenteral nutrition. Government health records show a rising global SBS and concomitant intestinal failure incidence. For instance, similar developments have been seen in EU-5 nations; the U.S. boasts a substantial SBS patient population estimated between 15,000 and 20,000. Demand for creative Short Bowel Syndrome drugs and treatments is spurred by this increasing patient load. Reflecting the growing orphan drug market for SBS and continuous clinical trials for Short Bowel Syndrome that concentrate on new medicines to improve patient outcomes and lower complications, regulatory agencies have approved many orphan pharmaceuticals aimed at SBS.
Drivers
Tissue Engineering and Regenerative Medicine Advancements Propel Industry Expansion.
The market for short bowel syndrome (SBS) is being much shaped by recent advances in regenerative medicine. Knockout of the SATB2 gene in preclinical mice reprogrammed cells of the upper colon to operate like small intestinal cells, therefore restoring nutrition absorption and reversing weight loss, according to a study published in Gastroenterology in April 2025. This creative method could result in future gene therapies for SBS, providing a possible substitute for small bowel transplants, which have problems, including organ shortage and the necessity of harsh immunosuppression. Funded by the EU, the INTENS initiative aims to overcome the shortfall of donor organs by creating patient-specific jejunal transplants utilizing autologous tissue, therefore removing the need for immunosuppression.
Autologous tissue engineering, a technique employing cells or tissues taken from the same person, is part of the functional bowel rebuilding method. Studies carried out during the project also revealed parallels between the metabolic profiles of the colon scaffolds engineered materials used to generate new tissues for medicinal use—and the small intestine. These parallels imply that the small intestine and colon scaffolds may be used alternatively as platforms for intestinal engineering by scientists. These developments in tissue engineering and regenerative medicine point to a change toward more patient-centric and efficient solutions, hence fueling the growth of the SBS treatment market.
Restraints
High Treatment Costs and Limited Access Restrain Market Growth
Though there are now more treatment choices, the great expenses related to SBS management still greatly limit market expansion. The main course of treatment for SBS is nutrition support, which can be somewhat costly, involving parenteral nourishment. Furthermore, the complexity of addressing SBS via multidisciplinary approaches calls for significant healthcare infrastructure and knowledge, which might not always be available, thus limiting market expansion. Some people with short bowel syndrome may get pancreatic enzyme replacement therapy, including bile-acid resins such as cholestyramine and pancrelipase. Though non-transplant and transplant operations sometimes define surgical choices for short bowel syndrome, as surgical skills advance, they may finally be deemed a front-line solution. Many patients may find it difficult to get the required treatment without enough financial support and easily available healthcare resources, thereby restricting the total potential growth of the SBS market.
By Type
The GLP-2 segment dominated the SBS market in 2024 with a dominant 94% revenue share, driven by the great acceptance of FDA-approved medications such as teduglutide (marketed as Gattex/Revestive). Analogues of glucagon-like peptide-2 (GLP-2), Teduglutide, improve the quality of life for SBS patients by lowering parenteral nutrition reliance and increasing intestinal absorption. Government regulatory approvals and orphan drug designations have strengthened the legitimacy of GLP-2 therapies and helped them to be more widely used, particularly in developed areas like the United States and Europe. Recent clinical trials, including phase 2 and 3 investigations of new GLP-2 analogues such as apraglutide and glepaglutide, highlight the great R&D effort on expanding the SBS pipeline drugs portfolio, hence driving market growth for Short Bowel Syndrome.
On the other hand, the growth hormone segment is expected to rise greatly since it might raise lean body mass and body weight in SBS patients. Still, adverse problems and inadequate adult efficacy data help to restrain its acceptance. Future use in both adult and pediatric SBS populations is predicted to be driven by continuous research on refining growth hormone therapy regimens to increase safety and efficacy, highlighted in government health reports.
By Distribution Channel
Driven by growing patient demand for quick access to drugs and the development of e-commerce platforms in healthcare, the online and retail pharmacy sector led the SBS treatment market in 2024. The emergence of telemedicine and home healthcare specialty clinics has helped this trend to be encouraged even more by allowing patients with intestinal failure to control their condition remotely, and hence lower hospital visits. Especially in industrialized nations, government healthcare projects encouraging digital health uptake and remote patient monitoring have sped this change.
The hospital pharmacies are predicted to expand noticeably during the projection period as more complicated SBS patients needing specialized therapies and acute care increase demand. Administering parenteral nourishment and controlling SBS-related problems depend on hospitals, which remain indispensable. Rising hospitalization rates for SBS patients shown by government healthcare data from the United States and Europe, promote the development of hospital pharmacy services specifically targeted to SBS treatments. Recent advances include improved SBS patient outcomes and demand for hospital-dispensed medications employing integration of multidisciplinary care models and improved clinical protocols in hospitals.
North America region dominated the market with held 72% market share and is valued at USD 1.16 billion, the global short bowel syndrome (SBS) market in 2024 is expected to grow significantly. By 2032, the U.S. short bowel syndrome market size is expected to rise to USD 2.09 billion. Strong government funding for rare illness therapies, advanced healthcare infrastructure, and a sizable SBS patient population drive this predominance mostly. The Crohn's & Colitis Foundation estimates that SBS affects 10,000 to 20,000 people in the United States; many of them need parenteral nutrition as intestinal failure results. Funding for SBS research has been raised by the US government, best shown by a 2021 NIH grant of USD 1.9 million to investigate new drugs aiming at SBS-related multisystem damage. This money promotes strong short bowel syndrome market expansion in the area, together with high adoption rates of FDA-approved SBS drugs such as teduglutide.
With the second-largest percentage of the global SBS market, Europe is Along with thorough patient care systems, the presence of new biotechnology businesses emphasizing creative SBS therapies and biologics drives market growth. Particularly for GLP-2 analogues, which are fundamental for the short bowel syndrome therapeutics market, the area gains from a well-established healthcare system and rising clinical trials for short bowel syndrome.
The forecast period shows Asia Pacific to be the fastest-growing area, predicted to have the greatest CAGR. Rising awareness of rare diseases in nations such as India, Japan, and Australia, along with increasing R&D spending and expanding GLP-2-based medication clinical trials, supports this expansion. Key elements increasing the worldwide short bowel syndrome market growth in this area are the direct presence of big pharmaceutical corporations and expanding healthcare infrastructure. Since SBS is underdiagnosed in many areas of Asia, government projects targeted at enhancing diagnosis and treatment access are further driving the market.
Rising awareness and bettering healthcare infrastructure are helping Latin America and the Middle East and Africa (LAMEA) areas to see slow development. Still, market penetration is small when compared to North America and Europe. Supported by government health initiatives concentrating on uncommon diseases and gastrointestinal disorders, efforts to increase distribution channels and deliver new SBS therapies are continuous.
The key Short Bowel Syndrome Companies are Swedish Orphan Biovitrum AB, Emmaus Life Sciences, Inc., OxThera AB, Merck & Co., Inc., Novartis AG, Wellspect Healthcare (Dentsply Sirona Company), OPKO Health, Inc., Pfizer Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and others
The worldwide SBS market is estimated to reach USD 6.4 billion by 2030 from USD 2 billion in 2024. Advances in home healthcare and telemedicine complement the predicted expansion that GLP-2 medications bring about.
Phase 2 clinical trials were cleared by Hanmi Pharmaceutical's GLP-2 analogue HM15912 in January 2025, thereby greatly changing the SBS pipeline pharmaceuticals scene.
| Report Attributes | Details |
|---|---|
| Market Size in 2024 | USD 1.61 Billion |
| Market Size by 2032 | USD 3.74 Billion |
| CAGR | CAGR of 11.16% From 2025 to 2032 |
| Base Year | 2024 |
| Forecast Period | 2025-2032 |
| Historical Data | 2021-2023 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Type (Growth Hormone, GLP-2, and Glutamine) • By Distribution Channel (Hospital Pharmacies, and Online & Retail Pharmacies) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) |
| Company Profiles | Swedish Orphan Biovitrum AB, Emmaus Life Sciences, Inc., OxThera AB, Merck & Co., Inc., Novartis AG, Wellspect Healthcare (Dentsply Sirona Company), OPKO Health, Inc., Pfizer Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and others |
Ans. The projected market size for the Short Bowel Syndrome Market is USD 3.74 billion by 2032.
Ans: The North America region dominated the Short Bowel Syndrome Market in 2024.
Ans. The CAGR of the Short Bowel Syndrome Market is 11.16% during the forecast period of 2025-2032.
Ans: High Treatment Costs and Limited Access Restrain Market Growth
Ans: The GLP-2 segment dominated the Short Bowel Syndrome Market.
Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.2 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Prescription and Therapeutic Trends (2024), by Region
5.2 Drug Volume and Usage Trends
5.3 Treatment Accessibility and Infrastructure Trends
5.4 Pipeline and Regulatory Activity (2024)
6. Competitive Landscape
6.1 List of Major Companies By Region
6.2 Market Share Analysis By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion Plans and New Product Launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Short Bowel Syndrome Market Segmentation By Type
7.1 Chapter Overview
7.2 Growth Hormone
7.2.1 Growth Hormone Trend Analysis (2021-2032)
7.2.2 Growth Hormone Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 GLP-2
7.3.1 GLP-2 Market Trends Analysis (2021-2032)
7.3.2 GLP-2 Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4 Glutamine
7.4.1 Glutamine Market Trends Analysis (2021-2032)
7.4.2 Glutamine Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Short Bowel Syndrome Market Segmentation By Distribution Channel
8.1 Chapter Overview
8.2 Hospital Pharmacies
8.2.1 Hospital Pharmacies Market Trends Analysis (2021-2032)
8.2.2 Hospital Pharmacies Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 Online & Retail Pharmacies
8.3.1 Online & Retail Pharmacies Market Trends Analysis (2021-2032)
8.3.2 Online & Retail Pharmacies Market Size Estimates and Forecasts to 2032 (USD Billion)
9. Regional Analysis
9.1 Chapter Overview
9.2 North America
9.2.1 Trends Analysis
9.2.2 North America Short Bowel Syndrome Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
9.2.3 North America Short Bowel Syndrome Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.2.4 North America Short Bowel Syndrome Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
9.2.5 USA
9.2.5.1 USA Short Bowel Syndrome Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.2.5.2 USA Short Bowel Syndrome Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
9.2.6 Canada
9.2.6.1 Canada Short Bowel Syndrome Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.2.6.2 Canada Short Bowel Syndrome Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
9.2.7 Mexico
9.2.7.1 Mexico Short Bowel Syndrome Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.2.7.2 Mexico Short Bowel Syndrome Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
9.3 Europe
9.3.1 Trends Analysis
9.3.2 Europe Short Bowel Syndrome Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
9.3.3 Europe Short Bowel Syndrome Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.3.4 Europe Short Bowel Syndrome Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
9.3.5 Germany
9.3.5.1 Germany Short Bowel Syndrome Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.3.5.2 Germany Short Bowel Syndrome Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
9.3.6 France
9.3.6.1 France Short Bowel Syndrome Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.3.6.2 France Short Bowel Syndrome Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
9.3.7 UK
9.3.7.1 UK Short Bowel Syndrome Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.3.7.2 UK Short Bowel Syndrome Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
9.3.8 Italy
9.3.8.1 Italy Short Bowel Syndrome Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.3.8.2 Italy Short Bowel Syndrome Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
9.3.9 Spain
9.3.9.1 Spain Short Bowel Syndrome Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.3.9.2 Spain Short Bowel Syndrome Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
9.3.10 Poland
9.3.10.1 Poland Short Bowel Syndrome Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.3.10.2 Poland Short Bowel Syndrome Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
9.3.11 Turkey
9.3.11.1 Turkey Short Bowel Syndrome Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.3.11.2 Turkey Short Bowel Syndrome Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
9.3.12 Rest of Europe
9.3.12.1 Rest of Europe Short Bowel Syndrome Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.3.12.2 Rest of Europe Short Bowel Syndrome Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
9.4 Asia Pacific
9.4.1 Trends Analysis
9.4.2 Asia Pacific Short Bowel Syndrome Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
9.4.3 Asia Pacific Short Bowel Syndrome Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.4.4 Asia Pacific Short Bowel Syndrome Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
9.4.5 China
9.4.5.1 China Short Bowel Syndrome Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.4.5.2 China Short Bowel Syndrome Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
9.4.6 India
9.4.5.1 India Short Bowel Syndrome Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.4.5.2 India Short Bowel Syndrome Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
9.4.5 Japan
9.4.5.1 Japan Short Bowel Syndrome Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.4.5.2 Japan Short Bowel Syndrome Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
9.4.6 South Korea
9.4.6.1 South Korea Short Bowel Syndrome Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.4.6.2 South Korea Short Bowel Syndrome Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
9.4.7 Singapore
9.4.7.1 Singapore Short Bowel Syndrome Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.4.7.2 Singapore Short Bowel Syndrome Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
8.4.8 Australia
8.4.8.1 Australia Short Bowel Syndrome Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
8.4.8.2 Australia Short Bowel Syndrome Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
9.4.9 Rest of Asia Pacific
9.4.9.1 Rest of Asia Pacific Short Bowel Syndrome Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.4.9.2 Rest of Asia Pacific Short Bowel Syndrome Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
9.5 Middle East & Africa
9.5.1 Trends Analysis
9.5.2 Middle East & Africa Short Bowel Syndrome Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
9.5.3 Middle East & Africa Short Bowel Syndrome Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.5.4 Middle East & Africa Short Bowel Syndrome Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
9.5.5 UAE
9.5.5.1 UAE Short Bowel Syndrome Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.5.5.2 UAE Short Bowel Syndrome Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
9.5.6 Saudi Arabia
9.5.6.1 Saudi Arabia Short Bowel Syndrome Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.5.6.2 Saudi Arabia Short Bowel Syndrome Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
9.5.7 Qatar
9.5.7.1 Qatar Short Bowel Syndrome Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.5.7.2 Qatar Short Bowel Syndrome Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
9.5.8 South Africa
9.5.8.1 South Africa Short Bowel Syndrome Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.5.8.2 South Africa Short Bowel Syndrome Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
9.5.9 Middle East & Africa
9.5.9.1 Middle East & Africa Short Bowel Syndrome Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.5.9.2 Middle East & Africa Short Bowel Syndrome Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
9.6 Latin America
9.6.1 Trends Analysis
9.6.2 Latin America Short Bowel Syndrome Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
9.6.3 Latin America Short Bowel Syndrome Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.6.4 Latin America Short Bowel Syndrome Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
9.6.5 Brazil
9.6.5.1 Brazil Short Bowel Syndrome Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.6.5.2 Brazil Short Bowel Syndrome Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
9.6.6 Argentina
9.6.6.1 Argentina Short Bowel Syndrome Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.6.6.2 Argentina Short Bowel Syndrome Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
9.6.7 Rest of Latin America
9.6.7.1 Rest of Latin America Short Bowel Syndrome Market Estimates and Forecasts, By Type (2021-2032) (USD Billion)
9.6.7.2 Rest of Latin America Short Bowel Syndrome Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10. Company Profiles
10.1 Orphan Biovitrum AB
10.1.1 Company Overview
10.1.2 Financial
10.1.3 Product / Services Offered
10.1.4 SWOT Analysis
10.2 Emmaus Life Sciences, Inc.
10.2.1 Company Overview
10.2.2 Financial
10.2.3 Product/ Services Offered
10.2.4 SWOT Analysis
10.3 OxThera AB
10.3.1 Company Overview
10.3.2 Financial
10.3.3 Product/ Services Offered
10.3.4 SWOT Analysis
10.4 Novartis AG
10.4.1 Company Overview
10.4.2 Financial
10.4.3 Product/ Services Offered
10.4.4 SWOT Analysis
10.5 Merck & Co., Inc.
10.5.1 Company Overview
10.5.2 Financial
10.5.3 Product/ Services Offered
10.5.4 SWOT Analysis
10.6 Wellspect Healthcare (Dentsply Sirona Company)
10.6.1 Company Overview
10.6.2 Financial
10.6.3 Product/ Services Offered
10.6.4 SWOT Analysis
10.7 OPKO Health, Inc.
10.7.1 Company Overview
10.7.2 Financial
10.7.3 Product/ Services Offered
10.7.4 SWOT Analysis
10.8 Pfizer Inc.
10.8.1 Company Overview
10.8.2 Financial
10.8.3 Product/ Services Offered
10.8.4 SWOT Analysis
10.9 Takeda Pharmaceutical Company Limited
10.9.1 Company Overview
10.9.2 Financial
10.9.3 Product/ Services Offered
10.9.4 SWOT Analysis
10.10 Teva Pharmaceutical Industries Ltd.
10.10.1 Company Overview
10.10.2 Financial
10.10.3 Product/ Services Offered
10.10.4 SWOT Analysis
11. Use Cases and Best Practices
12. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Key Segments:
By Type
GLP-2
Glutamine
Growth Hormone
By Distribution Channel
Hospital Pharmacies
Online & Retail Pharmacies
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
US
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Poland
Turkey
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
UAE
Saudi Arabia
Qatar
South Africa
Rest of Middle East & Africa
Latin America
Brazil
Argentina
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Detailed Volume Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Competitive Product Benchmarking
Geographic Analysis
Additional countries in any of the regions
Customized Data Representation
Detailed analysis and profiling of additional market players
